<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="34975">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02651246</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 31915</org_study_id>
    <nct_id>NCT02651246</nct_id>
  </id_info>
  <brief_title>Optional Sub-study to Intraoperative Imaging With ICG Registry</brief_title>
  <official_title>Optional Sub-study to Intraoperative Imaging With ICG Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this optional sub-study is to record what tissues fluoresce in the
      operating room, and then to identify if these lesions are cancer when the histopathology is
      performed.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Number of tumor recurrence</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Lung, Prostate, Breast, Colon, Pancreatic, Renal, Bladder,Thyroid, Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut) Cancer</condition>
  <condition>Cancer of the Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut), Sarcoma Cancer</condition>
  <condition>Cancer of Neuro-onc, Parathyroid, Desmoid Tumors, Melanoma Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>data collection</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        cancer patients who undergo surgery and intraoperative imaging
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients &gt;= 18 years of age

          -  Patients presenting with any solid tumor and/or diseased tissue even benign nodules
             presumed to be resectable and are at risk for recurrence.

          -  Good operative candidate as determined by the treating physician and/or
             multidisciplinary team

          -  Subject capable of giving informed consent and participating in the process of
             consent.

        Exclusion Criteria:

          -  Pregnant women as determined by urinary or serum beta hCG within 72 hours of surgery

          -  Vulnerable patient populations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sunil Singhal, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sunil Singhal, MD, Ph.D</last_name>
    <phone>855-216-0098</phone>
    <email>PennCancerTrials@emergingmed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sunil Singhal, MD, PhD</last_name>
      <phone>855-216-0098</phone>
      <email>PennCancerTrials@emergingmed.com</email>
    </contact>
    <investigator>
      <last_name>Sunil Singhal, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 19, 2016</lastchanged_date>
  <firstreceived_date>January 6, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibromatosis, Aggressive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
